Veracyte (VCYT) Cost of Revenue (2012 - 2026)

Veracyte has disclosed Cost of Revenue across 15 years of filings, most recently posting $27.2 million for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $27.2 million, up 11.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $102.9 million (up 7.03% YoY), and the FY2025 annual result was $100.2 million, up 4.96% from the prior year.
• Cost of Revenue came in at $27.2 million for Q1 2026 at Veracyte, up from $25.9 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $27.2 million in Q1 2026 to a low of $22.6 million in Q3 2024.
• The 5-year median for Cost of Revenue is $24.5 million (2025), against an average of $24.8 million.
• Across the five-year window, Cost of Revenue soared 45.77% in 2022 and slipped 8.99% in 2024, its largest moves.
• Veracyte's Cost of Revenue stood at $24.1 million in 2022, then increased by 4.7% to $25.3 million in 2023, then fell by 1.73% to $24.8 million in 2024, then climbed by 4.5% to $25.9 million in 2025, then increased by 4.69% to $27.2 million in 2026.
• The last three Cost of Revenue figures came in at $27.2 million (Q1 2026), $25.9 million (Q4 2025), and $24.5 million (Q3 2025), per Business Quant data.